

Medtronic

Power to React

React & Solitaire - Clinical Evidence

안녕하세요, 존경하는 교수님.

최근 많은 교수님들께서 Stroke 시술시의 Combination Therapy에 큰 관심을 보여주고 계시는데요, 이에 따라 이번 뉴스레터 에서는 저희 Medtronic의 제품으로 연구된 Combination study 결과를 소개해드리고자 합니다.

이번 Global Inspire-S 분석 결과는 급성 허혈 뇌졸중(AIS) 환자에서 React 카테터와 Solitaire Combination Therapy의 real-world safety와 effectiveness를 뒷받침 하고 있습니다.

INSPIRE-S


Innovative Neurovascular Product Surveillance **RE**gistry-Acute Ischemic **Stroke**

A neurovascular registry to study innovative AIS approved devices

Study design

- Prospective, global registry¹
- >800 AIS patients enrolled to date, across 33 sites worldwide² (29 Western European countries)²
- Core-lab adjudicated
- Clinical events committee (CEC) adjudicated
- 3 cohorts based on first pass technique:





Purpose

To present the results for **397** patients from the combination therapy cohort.

Primary objective

Good functional outcomes as measured by a modified Rankin Scale (mRS) score of 0-2, or return to pre-stroke mRS at 90 days post-intervention.

Additional outcomes

Final successful revascularization, first pass revascularization, and safety outcomes.

Procedural characteristics

Combination Therapy % (n/Total N)


Thrombectomy Method at 1st Pass	
Solitaire™ (Platinum and X)	100% (397/397)
React™	76.1% (302/397)
React™ 68	37.8% (150/397)
React™ 71	38.3% (152/397)
Other Aspiration Catheter*	23.9% (95/397)
Balloon Guide Catheter used at 1st Pass	39.5% (157/397)

*Enrollment guide was updated in March 2022 to include use of other market-approved aspiration catheters in conjunction with Solitaire™ as the primary treatment device.


Preliminary Results

First Pass Revascularization


eTICI ≥2b50




eTICI ≥2b67



eTICI ≥2c



eTICI = 3



Final Successful Revascularization

Combination Therapy %

eTICI ≥ 2b50	93.4%
eTICI ≥ 2b67	88.8%
eTICI ≥ 2c	75.6%
eTICI = 3	52.7%

397 Patients treated with Combination Therapy

100% Solitaire™ (Platinum and X) used at 1st pass

76.1% React™ used at 1st pass

93.4% Final Revascularization eTICI ≥ 2b50

48.6% 1st pass effect eTICI≥2c

1.5% Rate of sICH

54.1% mRS 0-2

Key Conclusions:

이번 Inspire-S Global Registry를 통하여 Combination 시술시
 $\frac{3}{4}$ 의 환자가 주목할 만한 높은 revascular를 보이고 (Final eTICI>2c 75.6%)
 $\frac{1}{2}$ 의 환자가 single pass 로 recan 하는 (1st pass effect eTICI>2c 48.6%)
Combination의 뚜렷이 좋은 결과를 확인할 수 있었습니다.

Conclusion

This analysis of INSPIRE-S supports the real-world safety and effectiveness of the use of the Solitaire™ Revascularization Device in Combination Therapy, primarily with the React™ Catheter, in patients with AIS.

INSPIRE-S

A neurovascular registry to study innovative AIS approved devices



References

¹INSPIRE-S Analysis Plan V3.0.

²Medtronic data on file for INSPIRE-S Registry

Presented by Marc Ribo at the European Stroke Conference Basel, 15-17 May 2024

Presented by Marc Ribo at ISC Phoenix, 7-9 February 2024

ISC <https://professional.heart.org/en/meetings/international-stroke-conference>

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at

[medtronic.eu](https://www.medtronic.eu)

메드트로닉(www.medtronic.com)은 150개 이상의 국가에서 90,000명 이상의 임직원과 함께하고 있는 메드트로닉은 전 세계적으로 메드트로닉의 긍정적인 영향력을 확장할 수 있는 특별한 가능성이 있다고 믿습니다. 메드트로닉은 헬스케어 테크놀로지에 대한 접근성을 확대하고, 포용성과 다양성 및 형평성을 증진시키며, 지구를 보호하기 위해 노력하고 있습니다.

Medtronic